These results suggest that the combination of BRAF/MEK inhibitors and CD47 blocking antibodies may have synergistic effect by promoting macrophages phagocytosis of melanoma cells and may further trigger specific immune specific immunity response by presenting processed tumor cell antigens to T cells. Here, MAP2K7 is linked to melanoma.